Juno Diagnostics is a technology company.
Juno Diagnostics has raised $25.0M across 1 funding round.
Juno Diagnostics has raised $25.0M in total across 1 funding round.
Juno Diagnostics was a San Diego-based biotechnology company founded in 2017 that developed genetic testing solutions, primarily a non-invasive prenatal testing (NIPT) product aimed at simplifying sample collection without phlebotomy, reducing costs, and shortening lead times to improve access to vital health information like fetal genetic risks.[1][2][3] It served expectant parents and healthcare providers seeking affordable prenatal screening for conditions such as Down syndrome and cystic fibrosis, addressing barriers in traditional NIPT methods that require clinical blood draws.[1][2] The company raised $25M in funding but ceased operations on July 31, 2023, marking it as a "dead" startup despite early promise in the precision medicine space.[1]
Juno Diagnostics emerged in 2017 in San Diego, California, focusing on novel genetic testing to democratize access to prenatal health data.[1][2][3] Specific founders are not detailed in available records, but the company quickly positioned itself in the biotech sector with its lead NIPT product, which innovated by bypassing phlebotomy requirements.[1][2] Early traction included a $25M funding round, participation in events like the 2023 Precision Medicine World Conference, and growth amid rising demand for non-invasive testing, though it ultimately shut down in July 2023 due to undisclosed challenges.[1][2]
(Note: Post-2023 shutdown limits current differentiators; a separate entity, Juno Genetics, offers unrelated preimplantation genetic testing.[5])
Juno Diagnostics rode the wave of advancing prenatal DNA sequencing and non-invasive testing trends, fueled by improved data analysis for detecting disorders like Down syndrome amid North America's market dominance in 2024.[1] Its timing aligned with precision medicine growth, ethical advancements, and integrations like prenatal genetic counseling, alongside industry moves such as Myriad Genetics' acquisition of Gateway Genomics to bolster women's health portfolios.[1] Though it ceased operations in 2023, Juno exemplified competitive pressures from giants like Illumina and Roche, influencing ecosystem pushes for accessible genetics while highlighting startup risks in a consolidating biotech field.[1]
Juno Diagnostics' story underscores the high-stakes volatility in biotech, where innovation meets execution hurdles—its 2023 shutdown after $25M raised signals potential pivots like acquisition or tech licensing that never materialized.[1] No active future exists for the company itself, but trends in NIPT accuracy, regulatory easing, and AI-driven genomics will propel similar ventures, potentially reviving its accessibility ethos through successors.[1] Investors eyeing prenatal tech should note Juno's legacy: breakthroughs demand sustainable scaling beyond product novelty.
Juno Diagnostics has raised $25.0M in total across 1 funding round.
Juno Diagnostics's investors include BoxOne Ventures, Eunoia Capital Partners, Harmonix Fund, Perceptive Advisors, Ayman AlAbdallah.
Juno Diagnostics has raised $25.0M across 1 funding round. Most recently, it raised $25.0M Series A in May 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 1, 2021 | $25.0M Series A | BoxOne Ventures, Eunoia Capital Partners, Harmonix Fund, Perceptive Advisors, Ayman AlAbdallah |